Related Experiment Videos
[Induced sputum in allergology: techniques and indications]
S Boniface1, A M Lorec, M Badier
1Service de Pneumo-allergologie, UPRES EA 3287, univ-Méditerrannée, Pathologie respiratoire liée à l'environnement, Hôpital Sainte Marguerite, Marseille, France.
Revue Des Maladies Respiratoires
|August 6, 2002
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
[Impact of Rac1 activation on eosinophil degranulation in severe asthma].
Revue des maladies respiratoires·2025
[Written action plans for asthma control: How are they used by pulmonologists in France?]
Revue des maladies respiratoires·2024
Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma.
The Journal of asthma : official journal of the Association for the Care of Asthma·2022
[Update in severe asthma physiopathology and treatments].
La Revue de medecine interne·2019
[Allergen-derived peptide: A promising approach in asthma].
Revue des maladies respiratoires·2019
[Screening of children residing in the same household as patients with contagious tuberculosis].
Revue des maladies respiratoires·2026
[Factors associated with FEV1 evolution in cystic fibrosis patients treated by CFTR modulator tritherapy].
Revue des maladies respiratoires·2026
[Subacute pulmonary coccidioidomycosis: A differential diagnosis of lung cancer].
Revue des maladies respiratoires·2026
[Relevance of the ACT score in severe asthma with obesity: A pilot study].
Revue des maladies respiratoires·2026
[Automated analysis of mandibular movements for the screening of obstructive sleep apnea].
Revue des maladies respiratoires·2026
[Above and beyond BMI: Deciphering the lung cancer paradox].
Revue des maladies respiratoires·2026
Upadacitinib for refractory generalized lichen sclerosus: a case report and brief literature review.
Frontiers in immunology·2026
Case Report: A case report of bullous pemphigoid triggered by sintilimab (PD-1 inhibitor).
Frontiers in immunology·2026